^
Association details:
| Biomarker: | SMAD4 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
Excerpt:
The majority of these patients (n = 26 [55%]) received line anti-EGFR treatment as third-line systemic therapy. Specifically, patients received cetuximab (n = 39 [88%]), panitumumab (n = 4 [9%]), or both (n = 1 [2%])...Patients with SMAD4 mutations had significantly shorter progression-free survival durations than did those wild-type for SMAD4 (median, 111 days [95% CI, 96–125 days] versus 180 days [95% CI, 137–222 days]; HR, 0.32 [95% CI, 0.15–0.68]; p = 0.003).
DOI:
10.1371/journal.pone.0173345
